The InsidesTM Systemfi is the worlds leading provider of therapeutic chyme reinfusion solutions for the management of enterocutaneous fistula.
- $4.3 million raised by The Insides Company, thanks to Icehouse Ventures - AUCKLAND, August 1, 2019, Medical device developer The Insides Company (TICL) (previously Surgical Design Studio), which designs transformative products that… Continue Reading
- The Insides Company Granted Breakthrough Device Designation by US FDA - Press Release Source: The Insides Company (Surgical Design Studio1) On: Monday 10 June 2019 Companies: Surgical Design Studio The Insides… Continue Reading
- The Insides Company Appoints Commercialisation CEO - Press Release Source: The Insides Company Limited (Surgical Design Studio1.) On: 4:00pm Auckland, Wednesday 8 May 2019 Companies: The Insides… Continue Reading
Granted by the United States Food and Drug Administration (FDA)
Received the New Zealand Stock Exchange (NZX) Early Stage Companies Award in the 2019 TIN Report
People’s Choice for Best Project Award
Awarded the Innovative Research and Development Grant
Treating chyme as waste impedes the journey to recovery.
Chyme contains important nutrients and fluids that are lost when a patient with a loop ileostomy or enterocutaneous fistula empties their bag. This can result in complications such as:
Increased risk of Clostridium difficile
Missed or reduced chemotherapy doses
Patients who lose large volumes of chyme may require parenteral nutrition to maintain hydration and replace electrolytes. However, this is expensive and introduces new risks, including line sepsis, vascular damage and liver diseases.
Chyme reinfusion is the new standard.
Using The InsidesTM Systemfi to return chyme via the distal stoma restores the patient’s natural bowel continuity.
This can improve:
Studies have shown that restoring bowel continuity in patients on parenteral nutrition allowed them to return to an oral diet.